Evaluation of the change in sphingolipids in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 treated with arsenic trioxide

•An HPLC-ESI–MS/MS method was applied to investigate the changes in sphingolipids.•Arsenic trioxide (As2O3) was used to treat human U266 and MGC-803 cells.•The distributions of sphingolipids are different in the human U266 and MGC-803 cells.•The levels of Hex2Cer in human U266 cells decreased when t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Analytical technologies in the biomedical and life sciences, 2015-11, Vol.1004, p.98-107
Hauptverfasser: Zou, Jianhua, Ma, Xiaoqiong, Zhang, Guangji, Shen, Li, Zhou, Liting, Yu, Yu, Zhu, Fanfan, Chen, Zhe
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 107
container_issue
container_start_page 98
container_title Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
container_volume 1004
creator Zou, Jianhua
Ma, Xiaoqiong
Zhang, Guangji
Shen, Li
Zhou, Liting
Yu, Yu
Zhu, Fanfan
Chen, Zhe
description •An HPLC-ESI–MS/MS method was applied to investigate the changes in sphingolipids.•Arsenic trioxide (As2O3) was used to treat human U266 and MGC-803 cells.•The distributions of sphingolipids are different in the human U266 and MGC-803 cells.•The levels of Hex2Cer in human U266 cells decreased when treated with As2O3.•The levels of S1P and dhS1P in human MGC-803 cells decreased when treated with As2O3. Arsenic trioxide (As2O3) has been found to display anticancer activity against many types of tumors and has been developed into an anticancer drug in clinical treatments. Sphingolipids are membrane lipids that participate in many signal transduction pathways. In this paper, the changes in sphingolipids of the human multiple myeloma cell line U266 and the gastric cancer cell line MGC-803 treated with arsenic trioxide were investigated using an HPLC-ESI–MS/MS method. Analytes were separated by an XBridge BEH C8 column used for Cer, HexCer, LacCer and SM chromatographic separation, and a Capcell PAK MG II C18 column was used for Sph, dhSph, S1P and dhS1P chromatographic separation and gradient elution with acetonitrile–water containing 0.1% formic acid as a mobile phase. A tandem mass spectrometer QTrap in SRM mode was employed in combination with RPLC as a detector for quantitative analysis. The ceramide/sphingolipid internal standard (IS) mixture was used to quantify the levels of sphingolipids. The distributions of sphingolipids were found to be different in the human multiple myeloma cell line U266 and the gastric cancer cell line MGC-803. Ceramide (Cer), hexosylceramide (HexCer) and dihexosylceramide (Hex2Cer) levels in U266 cell line are higher than those in MGC-803 cell line. Additionally, sphingomyelin (SM), sphingosine-1-phosphate (S1P) and sphinganine-1-phosphate (dhS1P) levels in the MGC-803 cell line are higher than those in the U266 cell line. When treated with arsenic trioxide (1–5μM iAsIII(AsIII ions)), the levels of Hex2Cer in the human multiple myeloma cell line U266 decreased, and the levels of S1P and dhS1P in the human gastric cancer cell line MGC-803 decreased. The decrease of Hex2Cer, S1P and dhS1P in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 were observed when the concentration of iAsIII is 1.0μM. Therefore, arsenic trioxide exhibits anti-cancer activity by altering the sphingolipid pathway in the human multiple myeloma cell line U266 and the gastric cancer cell line MGC-803.
doi_str_mv 10.1016/j.jchromb.2015.09.015
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1723756510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1570023215301902</els_id><sourcerecordid>1723756510</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-f24bdb1c3788d4541e8e709eea2d672cb7c38400173369868ab086c8a79772353</originalsourceid><addsrcrecordid>eNqFkUFvFCEcxSdGY2vrR9Bw9DIjDDvAnIzZ1GpS48UmvREG_rvDhoERmNZ-lH5bmexqvPX0CPwefx6vqt4R3BBM2MdDc9BjDNPQtJh0De6bIi-qcyI4rSlndy_LuuO4xi1tz6o3KR0wJhxz-ro6a9mm2_CenVdPV_fKLSrb4FHYoTwC0qPye0DWozSP1u-Ds7M1ad1Yj8dlUh5Ni8t2doCmR3BhUkiDc8hZD-i2ZQwpb9BepRytRlp5DfE_4vv1thaYohxBZTDoweYRqZjAF7pYwm9r4LJ6tVMuwduTXlS3X65-br_WNz-uv20_39Sasi7Xu3YzmIFoyoUwJRUBARz3AKo1jLd64JqKzRqdUtYLJtSABdNC8Z7zlnb0ovpwvHeO4dcCKcvJpvWtykNYkiSF4h3rCC5od0R1DClF2Mk52knFR0mwXFuRB3lqRa6tSNzLIsX3_jRiGSYw_1x_ayjApyMAJei9hSiTtlB-zdgIOksT7DMj_gA6Q6EP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1723756510</pqid></control><display><type>article</type><title>Evaluation of the change in sphingolipids in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 treated with arsenic trioxide</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Zou, Jianhua ; Ma, Xiaoqiong ; Zhang, Guangji ; Shen, Li ; Zhou, Liting ; Yu, Yu ; Zhu, Fanfan ; Chen, Zhe</creator><creatorcontrib>Zou, Jianhua ; Ma, Xiaoqiong ; Zhang, Guangji ; Shen, Li ; Zhou, Liting ; Yu, Yu ; Zhu, Fanfan ; Chen, Zhe</creatorcontrib><description>•An HPLC-ESI–MS/MS method was applied to investigate the changes in sphingolipids.•Arsenic trioxide (As2O3) was used to treat human U266 and MGC-803 cells.•The distributions of sphingolipids are different in the human U266 and MGC-803 cells.•The levels of Hex2Cer in human U266 cells decreased when treated with As2O3.•The levels of S1P and dhS1P in human MGC-803 cells decreased when treated with As2O3. Arsenic trioxide (As2O3) has been found to display anticancer activity against many types of tumors and has been developed into an anticancer drug in clinical treatments. Sphingolipids are membrane lipids that participate in many signal transduction pathways. In this paper, the changes in sphingolipids of the human multiple myeloma cell line U266 and the gastric cancer cell line MGC-803 treated with arsenic trioxide were investigated using an HPLC-ESI–MS/MS method. Analytes were separated by an XBridge BEH C8 column used for Cer, HexCer, LacCer and SM chromatographic separation, and a Capcell PAK MG II C18 column was used for Sph, dhSph, S1P and dhS1P chromatographic separation and gradient elution with acetonitrile–water containing 0.1% formic acid as a mobile phase. A tandem mass spectrometer QTrap in SRM mode was employed in combination with RPLC as a detector for quantitative analysis. The ceramide/sphingolipid internal standard (IS) mixture was used to quantify the levels of sphingolipids. The distributions of sphingolipids were found to be different in the human multiple myeloma cell line U266 and the gastric cancer cell line MGC-803. Ceramide (Cer), hexosylceramide (HexCer) and dihexosylceramide (Hex2Cer) levels in U266 cell line are higher than those in MGC-803 cell line. Additionally, sphingomyelin (SM), sphingosine-1-phosphate (S1P) and sphinganine-1-phosphate (dhS1P) levels in the MGC-803 cell line are higher than those in the U266 cell line. When treated with arsenic trioxide (1–5μM iAsIII(AsIII ions)), the levels of Hex2Cer in the human multiple myeloma cell line U266 decreased, and the levels of S1P and dhS1P in the human gastric cancer cell line MGC-803 decreased. The decrease of Hex2Cer, S1P and dhS1P in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 were observed when the concentration of iAsIII is 1.0μM. Therefore, arsenic trioxide exhibits anti-cancer activity by altering the sphingolipid pathway in the human multiple myeloma cell line U266 and the gastric cancer cell line MGC-803.</description><identifier>ISSN: 1570-0232</identifier><identifier>EISSN: 1873-376X</identifier><identifier>DOI: 10.1016/j.jchromb.2015.09.015</identifier><identifier>PMID: 26454796</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Arsenic trioxide ; Arsenicals - pharmacology ; Cell Line, Tumor ; Chromatography, High Pressure Liquid ; HPLC-ESI–MS/MS ; Human gastric cancer cell line MGC-803 ; Human multiple myeloma cell line U266 ; Humans ; Multiple Myeloma - metabolism ; Multiple Myeloma - pathology ; Oxides - pharmacology ; Spectrometry, Mass, Electrospray Ionization ; Sphingolipids ; Sphingolipids - metabolism ; Stomach Neoplasms - metabolism ; Stomach Neoplasms - pathology ; Tandem Mass Spectrometry</subject><ispartof>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2015-11, Vol.1004, p.98-107</ispartof><rights>2015 Elsevier B.V.</rights><rights>Copyright © 2015 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-f24bdb1c3788d4541e8e709eea2d672cb7c38400173369868ab086c8a79772353</citedby><cites>FETCH-LOGICAL-c365t-f24bdb1c3788d4541e8e709eea2d672cb7c38400173369868ab086c8a79772353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jchromb.2015.09.015$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26454796$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zou, Jianhua</creatorcontrib><creatorcontrib>Ma, Xiaoqiong</creatorcontrib><creatorcontrib>Zhang, Guangji</creatorcontrib><creatorcontrib>Shen, Li</creatorcontrib><creatorcontrib>Zhou, Liting</creatorcontrib><creatorcontrib>Yu, Yu</creatorcontrib><creatorcontrib>Zhu, Fanfan</creatorcontrib><creatorcontrib>Chen, Zhe</creatorcontrib><title>Evaluation of the change in sphingolipids in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 treated with arsenic trioxide</title><title>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</title><addtitle>J Chromatogr B Analyt Technol Biomed Life Sci</addtitle><description>•An HPLC-ESI–MS/MS method was applied to investigate the changes in sphingolipids.•Arsenic trioxide (As2O3) was used to treat human U266 and MGC-803 cells.•The distributions of sphingolipids are different in the human U266 and MGC-803 cells.•The levels of Hex2Cer in human U266 cells decreased when treated with As2O3.•The levels of S1P and dhS1P in human MGC-803 cells decreased when treated with As2O3. Arsenic trioxide (As2O3) has been found to display anticancer activity against many types of tumors and has been developed into an anticancer drug in clinical treatments. Sphingolipids are membrane lipids that participate in many signal transduction pathways. In this paper, the changes in sphingolipids of the human multiple myeloma cell line U266 and the gastric cancer cell line MGC-803 treated with arsenic trioxide were investigated using an HPLC-ESI–MS/MS method. Analytes were separated by an XBridge BEH C8 column used for Cer, HexCer, LacCer and SM chromatographic separation, and a Capcell PAK MG II C18 column was used for Sph, dhSph, S1P and dhS1P chromatographic separation and gradient elution with acetonitrile–water containing 0.1% formic acid as a mobile phase. A tandem mass spectrometer QTrap in SRM mode was employed in combination with RPLC as a detector for quantitative analysis. The ceramide/sphingolipid internal standard (IS) mixture was used to quantify the levels of sphingolipids. The distributions of sphingolipids were found to be different in the human multiple myeloma cell line U266 and the gastric cancer cell line MGC-803. Ceramide (Cer), hexosylceramide (HexCer) and dihexosylceramide (Hex2Cer) levels in U266 cell line are higher than those in MGC-803 cell line. Additionally, sphingomyelin (SM), sphingosine-1-phosphate (S1P) and sphinganine-1-phosphate (dhS1P) levels in the MGC-803 cell line are higher than those in the U266 cell line. When treated with arsenic trioxide (1–5μM iAsIII(AsIII ions)), the levels of Hex2Cer in the human multiple myeloma cell line U266 decreased, and the levels of S1P and dhS1P in the human gastric cancer cell line MGC-803 decreased. The decrease of Hex2Cer, S1P and dhS1P in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 were observed when the concentration of iAsIII is 1.0μM. Therefore, arsenic trioxide exhibits anti-cancer activity by altering the sphingolipid pathway in the human multiple myeloma cell line U266 and the gastric cancer cell line MGC-803.</description><subject>Arsenic trioxide</subject><subject>Arsenicals - pharmacology</subject><subject>Cell Line, Tumor</subject><subject>Chromatography, High Pressure Liquid</subject><subject>HPLC-ESI–MS/MS</subject><subject>Human gastric cancer cell line MGC-803</subject><subject>Human multiple myeloma cell line U266</subject><subject>Humans</subject><subject>Multiple Myeloma - metabolism</subject><subject>Multiple Myeloma - pathology</subject><subject>Oxides - pharmacology</subject><subject>Spectrometry, Mass, Electrospray Ionization</subject><subject>Sphingolipids</subject><subject>Sphingolipids - metabolism</subject><subject>Stomach Neoplasms - metabolism</subject><subject>Stomach Neoplasms - pathology</subject><subject>Tandem Mass Spectrometry</subject><issn>1570-0232</issn><issn>1873-376X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUFvFCEcxSdGY2vrR9Bw9DIjDDvAnIzZ1GpS48UmvREG_rvDhoERmNZ-lH5bmexqvPX0CPwefx6vqt4R3BBM2MdDc9BjDNPQtJh0De6bIi-qcyI4rSlndy_LuuO4xi1tz6o3KR0wJhxz-ro6a9mm2_CenVdPV_fKLSrb4FHYoTwC0qPye0DWozSP1u-Ds7M1ad1Yj8dlUh5Ni8t2doCmR3BhUkiDc8hZD-i2ZQwpb9BepRytRlp5DfE_4vv1thaYohxBZTDoweYRqZjAF7pYwm9r4LJ6tVMuwduTXlS3X65-br_WNz-uv20_39Sasi7Xu3YzmIFoyoUwJRUBARz3AKo1jLd64JqKzRqdUtYLJtSABdNC8Z7zlnb0ovpwvHeO4dcCKcvJpvWtykNYkiSF4h3rCC5od0R1DClF2Mk52knFR0mwXFuRB3lqRa6tSNzLIsX3_jRiGSYw_1x_ayjApyMAJei9hSiTtlB-zdgIOksT7DMj_gA6Q6EP</recordid><startdate>20151101</startdate><enddate>20151101</enddate><creator>Zou, Jianhua</creator><creator>Ma, Xiaoqiong</creator><creator>Zhang, Guangji</creator><creator>Shen, Li</creator><creator>Zhou, Liting</creator><creator>Yu, Yu</creator><creator>Zhu, Fanfan</creator><creator>Chen, Zhe</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151101</creationdate><title>Evaluation of the change in sphingolipids in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 treated with arsenic trioxide</title><author>Zou, Jianhua ; Ma, Xiaoqiong ; Zhang, Guangji ; Shen, Li ; Zhou, Liting ; Yu, Yu ; Zhu, Fanfan ; Chen, Zhe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-f24bdb1c3788d4541e8e709eea2d672cb7c38400173369868ab086c8a79772353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Arsenic trioxide</topic><topic>Arsenicals - pharmacology</topic><topic>Cell Line, Tumor</topic><topic>Chromatography, High Pressure Liquid</topic><topic>HPLC-ESI–MS/MS</topic><topic>Human gastric cancer cell line MGC-803</topic><topic>Human multiple myeloma cell line U266</topic><topic>Humans</topic><topic>Multiple Myeloma - metabolism</topic><topic>Multiple Myeloma - pathology</topic><topic>Oxides - pharmacology</topic><topic>Spectrometry, Mass, Electrospray Ionization</topic><topic>Sphingolipids</topic><topic>Sphingolipids - metabolism</topic><topic>Stomach Neoplasms - metabolism</topic><topic>Stomach Neoplasms - pathology</topic><topic>Tandem Mass Spectrometry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zou, Jianhua</creatorcontrib><creatorcontrib>Ma, Xiaoqiong</creatorcontrib><creatorcontrib>Zhang, Guangji</creatorcontrib><creatorcontrib>Shen, Li</creatorcontrib><creatorcontrib>Zhou, Liting</creatorcontrib><creatorcontrib>Yu, Yu</creatorcontrib><creatorcontrib>Zhu, Fanfan</creatorcontrib><creatorcontrib>Chen, Zhe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zou, Jianhua</au><au>Ma, Xiaoqiong</au><au>Zhang, Guangji</au><au>Shen, Li</au><au>Zhou, Liting</au><au>Yu, Yu</au><au>Zhu, Fanfan</au><au>Chen, Zhe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the change in sphingolipids in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 treated with arsenic trioxide</atitle><jtitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</jtitle><addtitle>J Chromatogr B Analyt Technol Biomed Life Sci</addtitle><date>2015-11-01</date><risdate>2015</risdate><volume>1004</volume><spage>98</spage><epage>107</epage><pages>98-107</pages><issn>1570-0232</issn><eissn>1873-376X</eissn><abstract>•An HPLC-ESI–MS/MS method was applied to investigate the changes in sphingolipids.•Arsenic trioxide (As2O3) was used to treat human U266 and MGC-803 cells.•The distributions of sphingolipids are different in the human U266 and MGC-803 cells.•The levels of Hex2Cer in human U266 cells decreased when treated with As2O3.•The levels of S1P and dhS1P in human MGC-803 cells decreased when treated with As2O3. Arsenic trioxide (As2O3) has been found to display anticancer activity against many types of tumors and has been developed into an anticancer drug in clinical treatments. Sphingolipids are membrane lipids that participate in many signal transduction pathways. In this paper, the changes in sphingolipids of the human multiple myeloma cell line U266 and the gastric cancer cell line MGC-803 treated with arsenic trioxide were investigated using an HPLC-ESI–MS/MS method. Analytes were separated by an XBridge BEH C8 column used for Cer, HexCer, LacCer and SM chromatographic separation, and a Capcell PAK MG II C18 column was used for Sph, dhSph, S1P and dhS1P chromatographic separation and gradient elution with acetonitrile–water containing 0.1% formic acid as a mobile phase. A tandem mass spectrometer QTrap in SRM mode was employed in combination with RPLC as a detector for quantitative analysis. The ceramide/sphingolipid internal standard (IS) mixture was used to quantify the levels of sphingolipids. The distributions of sphingolipids were found to be different in the human multiple myeloma cell line U266 and the gastric cancer cell line MGC-803. Ceramide (Cer), hexosylceramide (HexCer) and dihexosylceramide (Hex2Cer) levels in U266 cell line are higher than those in MGC-803 cell line. Additionally, sphingomyelin (SM), sphingosine-1-phosphate (S1P) and sphinganine-1-phosphate (dhS1P) levels in the MGC-803 cell line are higher than those in the U266 cell line. When treated with arsenic trioxide (1–5μM iAsIII(AsIII ions)), the levels of Hex2Cer in the human multiple myeloma cell line U266 decreased, and the levels of S1P and dhS1P in the human gastric cancer cell line MGC-803 decreased. The decrease of Hex2Cer, S1P and dhS1P in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 were observed when the concentration of iAsIII is 1.0μM. Therefore, arsenic trioxide exhibits anti-cancer activity by altering the sphingolipid pathway in the human multiple myeloma cell line U266 and the gastric cancer cell line MGC-803.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>26454796</pmid><doi>10.1016/j.jchromb.2015.09.015</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1570-0232
ispartof Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2015-11, Vol.1004, p.98-107
issn 1570-0232
1873-376X
language eng
recordid cdi_proquest_miscellaneous_1723756510
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Arsenic trioxide
Arsenicals - pharmacology
Cell Line, Tumor
Chromatography, High Pressure Liquid
HPLC-ESI–MS/MS
Human gastric cancer cell line MGC-803
Human multiple myeloma cell line U266
Humans
Multiple Myeloma - metabolism
Multiple Myeloma - pathology
Oxides - pharmacology
Spectrometry, Mass, Electrospray Ionization
Sphingolipids
Sphingolipids - metabolism
Stomach Neoplasms - metabolism
Stomach Neoplasms - pathology
Tandem Mass Spectrometry
title Evaluation of the change in sphingolipids in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 treated with arsenic trioxide
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T16%3A16%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20change%20in%20sphingolipids%20in%20the%20human%20multiple%20myeloma%20cell%20line%20U266%20and%20gastric%20cancer%20cell%20line%20MGC-803%20treated%20with%20arsenic%20trioxide&rft.jtitle=Journal%20of%20chromatography.%20B,%20Analytical%20technologies%20in%20the%20biomedical%20and%20life%20sciences&rft.au=Zou,%20Jianhua&rft.date=2015-11-01&rft.volume=1004&rft.spage=98&rft.epage=107&rft.pages=98-107&rft.issn=1570-0232&rft.eissn=1873-376X&rft_id=info:doi/10.1016/j.jchromb.2015.09.015&rft_dat=%3Cproquest_cross%3E1723756510%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1723756510&rft_id=info:pmid/26454796&rft_els_id=S1570023215301902&rfr_iscdi=true